Cocrystal Pharma, Inc. 8-K Filings

Cocrystal Pharma, Inc. (COCP) reported that its Board of Directors appointed Carol L. Brosgart as a director, effective August 12, 2026. The company states there are no arrangements or understandings with other persons regarding her selection, no family relationships with current directors or executive officers, and no related party transactions involving her that require disclosure under Item 404(a) of Regulation S-K.

Cocrystal Pharma, Inc. appointed Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026, and announced this in a press release dated August 17, 2026. The company describes itself as a clinical-stage biotechnology company developing antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses.

Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, government service, and biopharmaceutical consulting, including key roles in the development and regulatory approval of antiviral therapies Viread® and Hepsera® at Gilead Sciences. Cocrystal’s leadership highlights her anticipated contributions to the clinical development of CDI-988 for norovirus and to the broader antiviral pipeline.

Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with longtime investor OPKO Health, Inc., under which Cocrystal sold 5,474,053 shares of common stock at $0.9134 per share, the Nasdaq Consolidated Bid Price on the closing date, generating $5.0 million in gross proceeds.

The unregistered private placement to OPKO, an accredited investor, relied on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, and included no warrants or other derivative securities. Dr. Phillip Frost, OPKO’s Chairman and CEO, is co-founder, director and principal stockholder of Cocrystal. The company plans to use net proceeds to advance its preclinical and clinical antiviral programs, including lead norovirus candidate CDI-988, and for general corporate purposes and working capital, and expects topline data from its Phase 1b norovirus trial by the end of the fourth quarter of 2026.

Cocrystal Pharma, Inc. held its 2026 Annual Meeting of Stockholders on July 14, 2026. Stockholders voted on electing five directors, ratifying the independent auditor for the fiscal year ending December 31, 2026, and a possible adjournment to solicit additional proxies if needed.

All five director nominees were elected, with votes for each ranging from 5,914,522 to 6,293,331, and 2,860,552 broker non-votes recorded for each nominee. Stockholders ratified Weinberg & Company as the independent registered public accounting firm, with 9,181,034 votes for, 174,923 against, and 10,587 abstentions. Because Proposals 1 and 2 received sufficient support, the adjournment proposal was moot.

Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective immediately, under an employment offer letter. He will receive an initial annual base salary of $265,000 and an annual performance bonus targeted at 50% of base salary, tied to Board-set goals.

Sapirstein was granted 10-year stock options to purchase 235,000 shares at an exercise price of $1.05, vesting in four equal annual installments beginning June 3, 2027, with accelerated vesting upon a Change in Control or certain terminations. The Offer Letter also contemplates a potential additional grant of options to purchase another 235,000 shares six months after his start date, subject to performance targets and approvals. He replaces prior Co-CEOs Sam Lee and James Martin, who continue as President/Chief Scientific Officer and Chief Financial Officer, respectively.

Cocrystal Pharma has appointed James Sapirstein as Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. He succeeds former Co-CEOs Sam Lee and Jim Martin; Lee will remain President and become Chief Scientific Officer, while Martin continues as Chief Financial Officer. The company highlights Sapirstein’s extensive antiviral and biopharma leadership experience, including participation in 23 product launches and multiple business development deals. Cocrystal reiterates its focus on structure-based drug discovery to develop next-generation antiviral therapies targeting viruses such as norovirus, influenza, coronaviruses including SARS-CoV-2, and hepatitis C.

Cocrystal Pharma, Inc. reported new preclinical data showing its novel direct-acting antivirals have pan-viral activity against multiple viruses, including hantavirus, bunyavirus and influenza. These molecules target a highly conserved region of the viral replication enzyme, specifically the L-protein of Andes hantavirus, which is essential for replication and transcription.

The Company highlighted in vitro potency data with superior activity, including IC50 values below 50 nM against hantaan virus, a close relative of the Andes hantavirus strain linked to recent outbreaks. Cocrystal also noted that its first pan-viral protease inhibitor, CDI-988, has advanced into a Phase 1b norovirus challenge study in the United States, while it works to develop a pan-viral lead molecule and explore potential collaborations to address viral diseases that currently lack approved treatments or vaccines.

Cocrystal Pharma, Inc. filed a current report describing new clinical and scientific visibility for its oral norovirus drug candidate CDI-988. The company presented mechanism-of-action and early clinical data at the ICAR 2026 antiviral research conference, highlighting completed Phase 1 results and an ongoing Phase 1b human challenge study.

CDI-988, a first oral direct-acting 3CL protease inhibitor for norovirus, was generally safe and well tolerated in a randomized, double-blind, placebo-controlled Phase 1 trial in healthy adults at doses up to 1,200 mg, with no serious adverse events. The Phase 1b challenge trial at Emory University and the University of North Carolina plans to enroll up to 40 adults, with a fully enrolled initial cohort establishing infectivity of the norovirus GII.2 inoculum before prevention and treatment cohorts receiving 1,200 mg twice daily for five days.

The company notes that CDI-988 has U.S. FDA Fast Track designation for treatment and prophylaxis of norovirus infection, a disease with substantial global burden and no approved vaccines or therapies.

Cocrystal Pharma reports that the U.S. Food and Drug Administration has granted Fast Track designation to CDI-988, its oral, direct-acting protease inhibitor for treatment and prophylaxis of norovirus infection. Fast Track status is intended to accelerate development and regulatory review for serious conditions with unmet medical needs.

CDI-988 targets a highly conserved region of noroviruses and other 3CL viral proteases, and is being studied in an ongoing Phase 1b randomized, double-blind, placebo-controlled norovirus challenge trial in up to 40 healthy adults at Emory University School of Medicine. The study’s primary endpoint is reduction in clinical symptoms, with secondary endpoints including viral shedding, disease severity, safety, and pharmacokinetics.

Cocrystal Pharma reported a 2025 net loss of $8.8 million, or $0.78 per share, improving from a $17.5 million loss in 2024. Research and development expenses fell to $5.1 million from $12.5 million, and general and administrative costs declined to $4.0 million from $5.3 million.

The Company ended 2025 with $7.7 million in unrestricted cash, $5.9 million of working capital and 11.3 million common shares outstanding. Cocrystal advanced its antiviral pipeline, with a Phase 1b human challenge study of norovirus candidate CDI-988 underway and influenza A candidate CC-42344 completing an initial Phase 2a study with favorable safety.

Cocrystal Pharma, Inc. reported that board member Dr. Anthony Japour passed away on March 10, 2026. The company filed this current report to formally disclose his death as a change in its board of directors. The filing is signed by Co-Chief Executive Officer and Chief Financial Officer James Martin.

Cocrystal Pharma reported that the first subjects have been dosed in its Phase 1b norovirus human challenge study of CDI-988 at Emory University School of Medicine. The randomized, double-blind, placebo-controlled trial will enroll up to 40 healthy adults ages 18–49 who are intentionally infected with the GII.2 norovirus strain.

CDI-988 is a direct-acting, oral antiviral designed to inhibit a highly conserved region of the viral 3CL protease across known norovirus strains. The primary goal of the study is to assess efficacy versus placebo in reducing clinical symptoms, with secondary measures including viral shedding, disease severity, safety and pharmacokinetics. CDI-988 previously showed favorable safety and tolerability in a Phase 1 study up to a 1200 mg dose.

The company highlights norovirus as a major unmet medical need, with an estimated 685 million global cases and a $60 billion annual economic burden, and notes there are currently no approved treatments or vaccines for prevention or treatment.

Cocrystal Pharma filed a Form 8-K to share a press release about its oral norovirus protease inhibitor CDI-988. Initial progress from a Phase 1b norovirus challenge study will be presented at the 39th International Conference on Antiviral Research (ICAR2026) in Prague.

CDI-988 is described as the first oral antiviral drug candidate under development for prevention and treatment of acute norovirus gastroenteritis and is designed as a pan-viral 3CL protease inhibitor with potential activity against both noroviruses and coronaviruses. The company highlights the lack of approved antiviral therapies or vaccines for norovirus, which causes an estimated 200,000 deaths worldwide each year and significant economic burden, underscoring the potential medical need targeted by this program.

Cocrystal Pharma is granting new non-qualified stock options to its directors, executive officers and a consultant under its 2025 Equity Incentive Plan. The options have a 10-year term, an exercise price equal to the closing price on January 8, 2026, and become effective upon execution of the company’s standard option agreement.

Half of each grant vests on January 9, 2027, with the remaining half vesting in eight equal quarterly installments starting March 31, 2027, contingent on continued service. Directors such as Dr. Roger Kornberg and Dr. Philip Frost each received 24,615 options, while James Martin and Sam Lee each received 49,229 options, and a consultant received 40,000 options. The Compensation Committee also approved a $50,000 cash award to Dr. Kornberg for his role as chairman of the Scientific Advisory Board.

Cocrystal Pharma, Inc. reported that an Institutional Review Board at Emory University School of Medicine has approved initiation of a Phase 1b human challenge study with its compound CDI-988. The planned study is designed to evaluate CDI-988 both as a preventive and as a treatment for norovirus infections, a common cause of viral gastroenteritis. The company disclosed this development via a press release furnished as an exhibit to the report.

Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended September 30, 2025 and provided business updates. The company issued a press release on November 14, 2025 detailing these quarterly results and updates, and attached that release as Exhibit 99.1.

The report specifies that the earnings information under Item 2.02 and in Exhibit 99.1 is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless expressly stated.

Cocrystal Pharma entered a private placement with four accredited insiders, selling 739,426 units at $1.39 per unit. Each unit includes one common share and a warrant to buy two shares at $1.24 per share for 27 months. The transaction generated $1.03 million in gross proceeds.

The sale was conducted at-the-market under Nasdaq rules and carried no registration rights. The offering relied on Section 4(a)(2) and Rule 506(b) exemptions. If fully exercised, the warrants would be exercisable for 1,478,852 additional shares.

Cocrystal Pharma (COCP) filed an 8-K stating it announced receipt of a Small Business Innovation Research (SBIR) Phase I award from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID). The announcement was made on October 27, 2025.

The company furnished a press release as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure). The company states this information is furnished and not deemed “filed” under Section 18 of the Exchange Act, and it is not incorporated by reference into other filings. Cocrystal’s common stock trades on the Nasdaq Capital Market under the symbol COCP.

Cocrystal Pharma, Inc. entered into a securities purchase agreement for a registered direct stock offering and concurrent private placement of warrants. The company agreed to sell 2,764,710 common shares at $1.70 per share and issue Investor Warrants to purchase up to 5,529,420 additional shares at an initial exercise price of $1.50 per share. The transaction closed with gross proceeds of approximately $4.75 million before fees, with net proceeds intended for general corporate purposes and development of antiviral medicines. Investor Warrants are exercisable immediately, subject to 4.99% or, at the holder’s election, 9.99% beneficial ownership limits, and expire 24 months after effectiveness of a resale registration statement the company must file by October 10, 2025.

Cocrystal Pharma, Inc. filed a current report to share that it has released its financial results for the fiscal quarter ended June 30, 2025. On August 14, 2025, the company issued a press release detailing its results of operations and financial condition, which is furnished as Exhibit 99.1 to this report. The company notes that this information is furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other securities filings.